Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15479094 | 0.92 | RAB9A (0.42) | HCAR2ANO1ALOX15MAPK1RAB9A | |
| SCHEMBL12756637 | 0.91 | RAB9A (0.43) | HCAR2ANO1ALOX15MAPK1RAB9A | |
| SCHEMBL1490391 | 0.91 | HDAC1 (0.44) | HDAC1HDAC6HCAR2ANO1RAB9A | |
| SCHEMBL1490370 | 0.90 | HCAR2 (0.47) | HDAC1HDAC6HCAR2ALOX15MAPK1 | |
| SCHEMBL1490677 | 0.89 | HCAR2 (0.53) | HDAC1HDAC6HCAR2ANO1ALOX15 | |
| SCHEMBL1490658 | 0.88 | HCAR2 (0.48) | HDAC1HDAC6HCAR2ANO1ALOX15 | |
| SCHEMBL1490454 | 0.86 | HCAR2 (0.50) | HCAR2ALOX15MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL1490241 | 0.86 | ALOX15 (0.53) | HCAR2ALOX15MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL12756626 | 0.85 | RAB9A (0.44) | HDAC1HDAC6HCAR2ALOX15MAPK1 | |
| SCHEMBL1490397 | 0.84 | ANO1 (0.45) | HCAR2ANO1ALOX15MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2477982-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | HDAC1 2696/4885HDAC6 1662/4885HCAR2 343/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | HDAC1 2696/4885HDAC6 1662/4885HCAR2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.